BackgroundPolycystic ovary syndrome (PCOS) is a common and complex endocrine-metabolic disease. One of the well-documented characteristics of PCOS is obesity or overweightness. It is possible to be genetically predisposed to becoming obese or overweight, and several potentially causative single nucleotide polymorphisms (SNPs), such as rs9939609 (A/T) in the fat mass, and obesity-associated gene (FTO) and rs17782313 (T/C) in the melanocortin-4 receptor gene (MC4R), have been investigated. Further investigation of association between obesity-associated SNPs and PCOS susceptibility will contribute to a better understanding of the disease.MethodsIn the present study, we enrolled 733 patients with PCOS and 892 control subjects. The common variants FTO rs9939609 and MC4R rs17782313 were genotyped and their relationship with obesity-related traits was evaluated.ResultsRs9939609 and rs17782313 are associated with PCOS and obesity-related traits and profiles. The association found between PCOS and FTO rs9939609 (p = 0.0302) was attenuated after adjustment for BMI (p = 0.187). MC4R rs17782313 did not confer an increased risk for PCOS (p = 0.368) even after adjustments (p = 0.715). Interestingly, the interaction of FTO and MC4R polymorphisms was more significantly associated with PCOS (p = 0.031, adjusted for age and BMI). The FTO variant rs9939609 is associated with Chinese women with PCOS; however, this association is affected by BMI.ConclusionsThe combined pathogenic effect of FTO and MC4R polymorphisms indicates a direct role of the interaction between FTO and MC4R polymorphisms in the development of PCOS.
The fundamental target of the present survey is to explore the clinical impact of resveratrol in treating polycystic ovary syndrome. A number of 104 cases suffering from polycystic ovary syndrome admitted to the hospital from January 2018 to December 2020 were chosen as investigation subjects. The cases were categorized into two groups, namely control and study groups through the random number table technique, with 52 patients in each group. Patients in the group of study were considered to receive 100 % pure resveratrol (once daily, 1000 mg) and cases in the group of control received matched placebo. 3 mo later, the treatment effects of the two groups were scrutinized. Following the treating process, the length of ovary, endometrial thickness and number of sinus follicles in the research group were improved and substantially superior to those in the group of control (all p<0.05). The improvement in menstrual cycle and hair loss in the group of observation was considerably greater than that in the group of control (both p<0.05). Following the treatment, the levels of luteinizing hormone, estradiol and testosterone in the group of observation were less than those in the group of control, with statistically meaningful discrepancies (all p<0.05), but the follicle-stimulating hormone levels had no significant difference. After 3 mo of treating, the expression level of mitofusin-2 in the study group was substantially enhanced in comparison to that in the control group (p<0.05). Resveratrol improved sex hormone levels, menstrual irregularities, hair loss and ovarian function in cases suffering from polycystic ovary syndrome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.